SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glaxosmithkline Pharma creeps higher on reporting 34% rise in FY12

19 Feb 2013 Evaluate

Glaxosmithkline Pharmaceuticals is currently trading at Rs 2097.00, up by 5.60 points or 0.27% from its previous closing of Rs 2091.40 on the BSE.

The scrip opened at Rs 2100.00 and has touched a high and low of Rs 2117.40 and Rs 2091.75 respectively. So far 1005 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 10 has touched a 52 week high of Rs 2338.00 on 30-Mar-2012 and a 52 week low of Rs 1916.00 on 04-Jul-2012.

Last one week high and low of the scrip stood at Rs 2126.05 and Rs 2051.15 respectively. The current market cap of the company is Rs 17717.75 crore.

The promoters holding in the company stood at 50.67% while Institutions and Non-Institutions held 34.02% and 15.32% respectively.

GlaxoSmithKline Pharmaceuticals has reported 1.29% rise in its net profit at Rs 138.51 crore for fourth quarter ended December 31, 2012 as compared to Rs 136.74 crore for the same quarter in the previous year. Total income of the company has increased by 13.74% at Rs 704.34 crore for quarter under review as compared to Rs 619.25 crore for the quarter ended December 31, 2011.

For the entire 2012 fiscal, the company’s net profit surged 34.06% to Rs 577.26 crore from Rs 430.60 crore in the previous fiscal. The total income from operations went up by 11.37% to Rs 2823.78 crore from Rs 2535.50 crore in last year.

Glaxosmithkline Phar Share Price

2471.90 -19.50 (-0.78%)
24-Apr-2026 13:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1625.55
Dr. Reddys Lab 1337.60
Cipla 1300.65
Zydus Lifesciences 930.65
Lupin 2280.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×